Rayscape vs Riverain Technologies (2026)
Two thoracic imaging companies with different theories about why findings get missed. Rayscape detects and localizes across a large chest radiograph findings set, adds lung nodule work on computed tomography and compares against a patient's prior scans, with independent evaluation from a tuberculosis screening deployment. Riverain suppresses the vessels, on the argument that nodules are missed because vasculature hides them rather than because nobody looked, which changes what the radiologist sees rather than adding a list of what the model found. Those are complementary interventions and a lung program could justify both. The question for either is the same and neither answers it publicly: how does the model perform on your scanners and your protocols, because thoracic algorithms are unusually sensitive to acquisition and degrade quietly when they move.
- Findings breadth on chest radiography is substantial and it adds longitudinal comparison across a patient's prior scans, so change is visible rather than inferred.
- Independent evaluation in a tuberculosis screening context tests the product where radiologist capacity is thinnest, which is a harder setting than a reading room study.
- On premise or cloud integration, with the appliance model suiting institutions that cannot send images out.
- Vessel suppression on chest computed tomography and radiography is a specific technical approach to a specific problem, making nodules visible that vasculature obscures rather than listing more findings.
- Long established thoracic focus means the products have been in clinical use through several generations of scanner and protocol change.
- For a lung nodule program, a tool designed around the reason nodules are missed is different from a general findings detector.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Rayscape and Riverain Technologies are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Rayscape | Riverain Technologies |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2019 | 2000 |
| Headquarters | Timisoara, Romania | Miamisburg, Ohio, United States |
| Website | rayscape.ai | riveraintech.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Riverain Technologies
-
EHR / interoperability
Riverain Technologies made its ClearRead chest imaging AI available through RapidAI's Enterprise Platform, delivered over Rapid Edge Cloud and inside the Rapid Navigator Pro radiology workflow.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Romanian imaging AI company based in Timisoara whose Rayscape CXR analyzes chest X-rays, detecting and localizing 148 findings across 17 clinical classes, including tuberculosis, with bone suppressed views, an automatic cardiothoracic ratio and a normal or abnormal flag for worklist prioritization, and whose lung CT product detects nodules and compares them against a patient's prior scans. Its tuberculosis detection was evaluated independently in a South African tuberculosis prevalence survey published in The Lancet Digital Health in 2024.
Source: AI Health Index, August 2026
Ohio based company whose ClearRead software applies AI to chest CT and chest radiographs. ClearRead CT produces a vessel suppressed series with nodule detection marks, cleared by the FDA in 2016 (K161201) as an aid to the radiologist for pulmonary nodules on chest CT in an asymptomatic population, and extends to coronary artery calcium scoring (K242188, 2024).
Source: AI Health Index, August 2026
Questions buyers ask
How do Rayscape and Riverain Technologies work with the EHR?
Rayscape CXR integrates with the archive over DICOM, on premises or with a cloud archive, returning annotated images and structured outputs inside the native radiology viewer without a separate workspace, and sites can configure outputs, thresholds and visualization to their own reporting standards.
With Riverain Technologies, the 510(k) summaries describe delivery through the same DICOM network interface that supplies the CT series. The home page displays the names of health systems including the VA, Cleveland Clinic, Duke, Cedars-Sinai, Michigan Medicine and University Hospital Zurich, and reports more than 400 customer locations. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Rayscape and Riverain Technologies priced and sold?
The company's site has a pricing and plans page, and its AWS Marketplace listing for Rayscape CXR shows a free subscription with no end date alongside a 30 day money back guarantee on the current annual term, which suggests a paid annual contract behind the listing without stating its price or unit. The product can be procured through the marketplace and directly.
For Riverain Technologies, one route to buy is public: ClearRead CT is listed as an application in the Sectra Amplifier Marketplace, the application store for Sectra's PACS, with its integration and regulatory details and no price or licensing terms. The company's home page gives no licensing basis, whether per site, per study or across a health network. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Rayscape and Riverain Technologies handle patient data?
With Rayscape, the company's AWS Marketplace listing describes the product as software as a service, which sits uneasily with data never leaving the institution, and nothing says which deployments the commitment covers. Support, diagnostic and incident access usually carries exceptions.
In Riverain Technologies' case, the K161201 summary describes a postprocessing application that generates a secondary series from the lung CT; where that processing runs, what is retained afterward, whether customer studies are used to train or improve the models, and whether any de identification is applied are not stated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Rayscape and Riverain Technologies cover?
For Rayscape, the tuberculosis use has independent validation in a South African prevalence survey (The Lancet Digital Health, 2024), a population screening setting; the broader findings set and the CT product have no published per finding validation. The company reports clinical use at more than 300 sites in 18 countries, and its customer stories describe emergency and outpatient deployments.
With Riverain Technologies, the nodule detection clearance (K161201) covers chest CT in an asymptomatic population with both lungs in the field of view, supported by a multi reader study, so use on diagnostic chest CT in symptomatic patients falls outside the indication as summarized. Calcium scoring (K242188) and pneumothorax (K213566) are cleared; radiograph nodule detection has no US clearance stated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The two take different technical routes to thoracic imaging and should not be compared on findings counts: suppression changes what the reader sees, while detection lists what the model found, and a department may reasonably use both. Neither publishes a security attestation or trust center, and neither publishes pricing.
Ask both for performance on your own scanner mix and protocols, since thoracic algorithms are sensitive to acquisition parameters and a model validated elsewhere can degrade on your equipment without any visible signal in the output.